

## Special Issue

# Extracellular Vesicles: Research Advances in Cancer Treatment and Diagnostics

### Message from the Guest Editor

Extracellular vesicles (EVs) are membrane-bound vesicles released by cells that carry RNA, proteins, and lipids. These EVs can be derived directly from the plasma membrane or be endosomal-derived vesicles ranging in size from 30 to 1000 nm. EVs are considered essential in modulating the tumor microenvironment by tumor cells and are pivotal in the preparation of the pre-metastatic niche. Since cancer-derived EVs are enriched in differentially expressed RNAs and proteins and can be found in biological fluids such as blood and urine, EVs can be used as diagnostic tools, hopefully eliminating the need for surgically obtained biopsies. For therapeutic purposes, the inhibition of cancer exosomes has been successfully attempted. The stability and biocompatibility of EVs, combined with their capacity to carry molecules with therapeutic potential and their ability to target specific cell types, have led to their increasing use as vectors for therapeutic purposes. Therefore, this Special Issue welcomes all inputs on EV research with a focus on cancer treatment and diagnostic.

### Guest Editor

Dr. Luís R. Raposo

BioRG, Bioengineering and Sustainability Research Group, Lusofona University, Av. Campo Grande 376, 1749-024 Lisboa, Portugal

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/211918](https://mdpi.com/si/211918)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).